Nisa Investment Advisors
RAPP

Nisa Investment Advisors’s Rapport Therapeutics RAPP Stock Holding History

Nisa Investment Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.9K Buy
1,918
+565
+42% +$20.8K ﹤0.01% 1653
2026
Q1 		$42.3K Hold
1,353
– – ﹤0.01% 1732
2025
Q4 		$41K Hold
1,353
– – ﹤0.01% 1682
2025
Q3 		$40.2K Hold
1,353
– – ﹤0.01% 1691
2025
Q2 		$15.4K Buy
+1,353
New +$14.4K ﹤0.01% 2070
2025
Q1 		– Sell
-18
Closed -$319 – 3070
2024
Q4 		$319 Buy
+18
New +$399 ﹤0.01% 2890

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nisa Investment Advisors's RAPP Position: Q2 2026 in Review

Nisa Investment Advisors increased its Rapport Therapeutics (RAPP) stake by 42% in Q2 2026, buying an estimated $20.8K and bringing the position to 1,918 shares worth $79.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Nisa Investment Advisors first reported a position in RAPP in Q4 2024 and has held it in 6 quarters since. 56 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Nisa Investment Advisors held 1,918 shares of Rapport Therapeutics worth $79.9K as of Q2 2026.
  • Nisa Investment Advisors bought 565 Rapport Therapeutics shares in Q2 2026, an estimated $20.8K.
  • Rapport Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1653 holding.
  • Nisa Investment Advisors first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 56 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.